Literature DB >> 19659941

A traceback phenomenon can reveal the origin of prion infection.

Atsushi Kobayashi1, Masahiro Asano, Shirou Mohri, Tetsuyuki Kitamoto.   

Abstract

The transmission of prions to animals with incongruent prion protein (PrP) gene (referred to as cross-sequence transmission) results in a relatively long incubation period and can generate a new prion strain with unique transmissibility designated as a traceback phenomenon. For example, cross-sequence transmission of bovine spongiform encephalopathy (BSE) prions to human generated variant Creutzfeldt-Jakob disease (vCJD) prions which retained the transmissibility to mice expressing bovine PrP. This finding suggests that traceback studies could enable us to identify the origin of prions. There are two distinct phenotypes in dura mater graft-associated Creutzfeldt-Jakob disease (dCJD), with the majority represented by a non-plaque-type of dCJD (np-dCJD) and the minority by a plaque-type of dCJD (p-dCJD). To identify the origin of p-dCJD, we performed a traceback study using mice expressing human PrP with methionine homozygosity (129M/M) or valine homozygosity (129V/V) at polymorphic codon 129. The characteristics of p-dCJD such as the accumulation of abnormal isoform of PrP (PrP(Sc)) intermediate in size between type 1 and type 2, and plaque-type PrP deposition in the brain were maintained after transmission to the 129M/M mice. Furthermore, the 129V/V mice were more susceptible to p-dCJD prions than the 129M/M mice and produced type 2 PrP(Sc) that were identical in size to those from the 129V/V mice inoculated with sporadic CJD prions from a patient with 129V/V and type 2 PrP(Sc) (sCJD-VV2). In addition, we performed intracerebral transmission of sCJD-VV2 prions to the 129M/M mice as an experimental model for p-dCJD. These 129M/M mice showed the accumulation of the intermediate type PrP(Sc) and plaque-type PrP deposition in the brain. These results suggest that p-dCJD could be caused by cross-sequence transmission of sCJD-VV2 prions to individuals with the 129M/M genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659941     DOI: 10.1111/j.1440-1789.2008.00973.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  11 in total

1.  Distinctive properties of plaque-type dura mater graft-associated Creutzfeldt-Jakob disease in cell-protein misfolding cyclic amplification.

Authors:  Atsuko Takeuchi; Atsushi Kobayashi; Piero Parchi; Masahito Yamada; Masanori Morita; Shusei Uno; Tetsuyuki Kitamoto
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

2.  Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology?

Authors:  Atsushi Kobayashi; Piero Parchi; Masahito Yamada; Paul Brown; Daniela Saverioni; Yuichi Matsuura; Atsuko Takeuchi; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

3.  Experimental verification of a traceback phenomenon in prion infection.

Authors:  Atsushi Kobayashi; Nobuyuki Sakuma; Yuichi Matsuura; Shirou Mohri; Adriano Aguzzi; Tetsuyuki Kitamoto
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

4.  Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone.

Authors:  Ignazio Cali; Cathleen J Miller; Joseph E Parisi; Michael D Geschwind; Pierluigi Gambetti; Lawrence B Schonberger
Journal:  Acta Neuropathol Commun       Date:  2015-06-25       Impact factor: 7.801

Review 5.  Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems.

Authors:  Atsushi Kobayashi; Yuichi Matsuura; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  Acta Neuropathol Commun       Date:  2014-03-31       Impact factor: 7.801

6.  Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein.

Authors:  Atsushi Kobayashi; Yasushi Iwasaki; Hiroyuki Otsuka; Masahito Yamada; Mari Yoshida; Yuichi Matsuura; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  Acta Neuropathol Commun       Date:  2013-11-13       Impact factor: 7.801

Review 7.  Understanding Prion Strains: Evidence from Studies of the Disease Forms Affecting Humans.

Authors:  Marcello Rossi; Simone Baiardi; Piero Parchi
Journal:  Viruses       Date:  2019-03-29       Impact factor: 5.048

8.  The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins.

Authors:  Marcello Rossi; Hideaki Kai; Simone Baiardi; Anna Bartoletti-Stella; Benedetta Carlà; Corrado Zenesini; Sabina Capellari; Tetsuyuki Kitamoto; Piero Parchi
Journal:  Acta Neuropathol Commun       Date:  2019-04-08       Impact factor: 7.801

9.  Characterization of Sporadic Creutzfeldt-Jakob Disease and History of Neurosurgery to Identify Potential Iatrogenic Cases.

Authors:  Tsuyoshi Hamaguchi; Kenji Sakai; Atsushi Kobayashi; Tetsuyuki Kitamoto; Ryusuke Ae; Yosikazu Nakamura; Nobuo Sanjo; Kimihito Arai; Mizuho Koide; Fumiaki Katada; Masafumi Harada; Hiroyuki Murai; Shigeo Murayama; Tadashi Tsukamoto; Hidehiro Mizusawa; Masahito Yamada
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

10.  The Distribution of Prion Protein Allotypes Differs Between Sporadic and Iatrogenic Creutzfeldt-Jakob Disease Patients.

Authors:  Roger A Moore; Mark W Head; James W Ironside; Diane L Ritchie; Gianluigi Zanusso; Young Pyo Choi; Young Pyo Choi; Suzette A Priola
Journal:  PLoS Pathog       Date:  2016-02-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.